Photo from EORTC/LinkedIn
Oct 2, 2024, 13:22
The results of the TOPGEAR trial on gastric and GEJ adenocarcinoma – EORTC
EORTC (European Organisation for Research and Treatment of Cancer) shared a post on LinkedIn:
”We’re thrilled to announce the results of the TOPGEAR trial on gastric and gastroesophageal junction adenocarcinoma.
The study showed that the addition of preoperative chemoradiotherapy did not improve progression-free survival or overall survival compared to perioperative chemotherapy alone.
This breakthrough will impact clinical practice worldwide.
Source: EORTC/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14